Therefore, SGLT2 inhibitors have acquired more space in the cardiology field, having been suggested as a class I recommendation for HF regardless of the ejection fraction by the European Society of Cardiology guidelines (ESC) [35]. Here, SLC5A2 is linked to hydrops fetalis.